expressed from unexpressed genes and therefore defines a unique 'gene expression bar code' for each tissue type. To do this, we used the vast amount of publicly available data sets to assess the algorithm. With clinical data, we found near-perfect predictability of normal versus diseased tissue for three cancer studies and one Alzheimer's disease study. The bar-code method also discovers new tumor subsets in previously published breast cancer studies that can be used for the prognosis of tumor recurrence and survival time.
For any given gene and microarray platform, we wanted to know what intensity relates to no expression. A simple way to determine this would be to hybridize tissues for which we know the gene is not expressed and look at the distribution of the observed intensities. If a new sample is provided, and we want to know if this gene is expressed, we would simply compare the observed intensity to the previously formed distribution. For a single laboratory, creating this training data set is logistically impossible for two reasons: (i) we do not know what genes are expressed in which tissues and (ii) it would require various hybridizations for each gene. Fortunately, a preliminary version of such a data set already exists for some platforms/organisms. We downloaded raw data for more than a The vertical line is automatically drawn by the bar-code method, and distinguishes the intensity range associated with expressed and unexpressed genes. The orange, purple and green ticks denote the observed values with color denoting the call provided by the manufacturer. Absent calls are shown on top of the plot while present and marginal calls are shown on the bottom axis. For the gene in the top plot, the calls appear consistent with the plot, but these calls appear unable to distinguish expressed from unexpressed for the gene shown in the bottom row. The box plots stratify these calls by tissue. The horizontal line denotes the expressed-unexpressed boundary. hundred tissues from the public repositories and preprocessed with the same algorithm 1, [5] [6] [7] . Then, for each gene the intensity distribution was determined. Because it is expected that any given gene will only be expressed in some tissues, multiple modes should be observed. It is assumed that the lowest intensity mode is due to a lack of expression ( Fig. 1) . Genes that are expected to be expressed are coded with ones and the unexpressed coded with zeros. We refer to this information as the gene expression bar code (see Supplementary Methods online). We created bar codes for 118 human and 44 mouse tissues (Supplementary Tables 1  and 2 online; a dendrogram and heatmap displaying the bar codes and related summaries are available in Supplementary  Fig. 1 online) . We compared the bar code to the detection calls from the Affymetrix default analysis software (MAS 5.0). MAS 5.0 calls genes present, marginal or absent. With MAS 5.0, only 10% of the 22,215 genes represented in the 'human' array achieve the same call in all samples within the same tissue. This number increases to 48% using our approach ( Supplementary  Fig. 2a ,b online). We obtained similar results with mouse data ( Supplementary  Figs. 2c,d ). To assess sensitivity, we used results from a study that reported proteins present in various mouse tissues 8 . We mapped these proteins and found that the bar code was more sensitive at declaring genes present when the corresponding proteins were found in the tissue (Supplementary Fig. 2e) .
To demonstrate the utility of our algorithm we developed a classification scheme that assigns tissue types to unknown samples by comparing their bar code to predefined ones (using Euclidean distance). Various sample classification algorithms have been published by various groups for microarray data. Many of these were compared on the original expression estimates. Predictive analysis of microarrays (PAM) 9 produced the best results (data not shown).
We compared our approach to PAM using leave-one-out crossvalidation. We included tissues for which detailed annotation was available and there were 3 or more samples (see Supplementary Table 3 online for results, which include various clinical data sets [10] [11] [12] [13] [14] [15] [16] 
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sets not included in the cross-validation process ( Table 1) . Here only the bar code performed well, with similar accuracy to that of cross-validation. The fact that the bar code greatly outperformed PAM on the independent data sets is likely due to the lab or batch effect. Because studies usually target a particular tissue, a primary concern is that a strong lab effect will confound the ability to classify tissues from the ability to classify labs 2 . An example of the lab effect is shown in Supplementary Figure 3a online, where the correlations between samples from study E-AFMX-5 are high despite originating from a wide variety of tissues. The bar-code approach can remove many of these effects because subtle changes in intensity values are not strong enough to make an absent gene appear present, or vice versa. Notice that the bar code removes most of the correlations in the E-AFMX-5 study without removing the correlation between the brain tissues, both within the study and between studies (Fig. 2) . Another example of how the lab effect can affect results is described in Supplementary Results online and illustrated in Supplementary Figure 4 online.
To assess the ability of the bar-code algorithm to find undiscovered tissue subsets, we used data from three breast cancer studies that did not include normal breast tissue samples, but did include patient survival data [14] [15] [16] . We obtained the distance to all tissue bar codes, and 499 of 500 samples were classified as breast tumor (1 as bladder cancer). When we took out the breast tumor bar code, 37 of these samples were close to a variety of normal tissues and the other 463 samples to a variety of cancer tissues. We then formed good and bad prognosis bar codes using these 37 and 463 samples, respectively. Then we used this new bar code to reclassify the 500 samples. We iterated this procedure until the good and bad prognosis groups did not change. The final bar codes resulted in a powerful prognosis tool that outperformed the methods described in the original papers. The performance of our prognosis tool is summarized in Supplementary Results and illustrated in Supplementary  Tables 4-6 , and Supplementary Figure 5 online.
We expect the bar-code approach to classification and discovery presented in this paper to be improved in various ways. First, the classification algorithm implemented on the bar code was based on a very simple detection method and distance calculation. Many aspects can be optimized for prediction purposes. Second, as microarray technology improves so will the bar-code performance. In particular, the emergence of better gene annotation and arrays that probe for individual exons are the most promising developments. Finally, we have only implemented the bar code for two widely used platforms: Affymetrix HGU133A human array and MOE430 mouse array. As soon as enough public data are available, however, the bar code will be defined for other platforms. In conclusion, we would like to acknowledge the efforts from the Microarray Gene Expression Data (MGED) Society to promote the sharing of microarray data. The work presented here would not have been possible without the existing public repositories. In particular, the availability of raw data was key, as the methods used to process raw data into gene-level measurements also contribute to study-to-study variability 17, 18 . We hope the trend of sharing raw data continues, as we believe it to be necessary for microarray technology to fulfill its promise. PAM versus the bar code approach in six randomly selected data sets not included in the original database. The data described in Supplementary Table 1 were used to train the prediction algorithms. GEO, Gene Expression Omnibus.
